Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221269 · ClinicalTrials.gov registry record · NA
Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders
A NA study, sponsored by Butler Hospital.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04221269 is a NA study that has completed, run by Butler Hospital. The registered enrollment target is 30 participants.
The verdict
NCT04221269, a NA study, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.
Interventions
- BEHAVIORAL Enhanced Treatment as Usual
- BEHAVIORAL Coping Long-term with Active Suicide Program for Schizophrenia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2023-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221269
The ClinicalTrials.gov registry entry for NCT04221269 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enhanced Treatment as Usual is the first listed.
NCT04221269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04221269 about?
NCT04221269 is a clinical study titled "Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders". The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-...
What is the current status of trial NCT04221269?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2020-12-01. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04221269?
The interventions under investigation include: Enhanced Treatment as Usual (BEHAVIORAL), Coping Long-term with Active Suicide Program for Schizophrenia (BEHAVIORAL).
Who is sponsoring clinical trial NCT04221269?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.